Spots Global Cancer Trial Database for plx3397
Every month we try and update this database with for plx3397 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | NCT01042379 | Breast Neoplasm... Breast Cancer Breast Tumors Angiosarcoma TNBC - Triple-N... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance... | Standard Therap... AMG 386 with or... AMG 479 (Ganitu... MK-2206 with or... AMG 386 and Tra... T-DM1 and Pertu... Pertuzumab and ... Ganetespib ABT-888 Neratinib PLX3397 Pembrolizumab -... Talazoparib plu... Patritumab and ... Pembrolizumab -... SGN-LIV1A Durvalumab plus... SD-101 + Pembro... Tucatinib plus ... Cemiplimab Cemiplimab plus... Trilaciclib wit... SYD985 ([vic-]t... Oral Paclitaxel... Oral Paclitaxel... Amcenestrant Amcenestrant + ... Amcenestrant + ... ARX788 ARX788 + Cemipl... VV1 + Cemiplima... Datopotamab der... Datopotamab der... Zanidatamab Lasofoxifene Z-endoxifen ARV-471 ARV-471 + Letro... | 18 Years - | QuantumLeap Healthcare Collaborative | |
| PLX3397 KIT in Acral aNd mucOsal Melanoma | NCT02071940 | Malignant Melan... | PLX3397 | 18 Years - | The Christie NHS Foundation Trust | |
| Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma | NCT01217229 | Hodgkin Lymphom... | PLX3397 | 18 Years - | Daiichi Sankyo | |
| CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors | NCT02401815 | Gastrointestina... | PLX9486 Pexidartinib Sunitinib | 18 Years - | Cogent Biosciences, Inc. | |
| A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | NCT02452424 | Melanoma Non-small Cell ... Squamous Cell C... Gastrointestina... Ovarian Cancer | PLX3397 Pembrolizumab | 18 Years - | Daiichi Sankyo | |
| A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT | NCT04488822 | Tenosynovial Gi... | Pexidartinib | 18 Years - | Daiichi Sankyo | |
| Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC) | NCT01499043 | Prostate Cancer | PLX3397 | 18 Years - | Daiichi Sankyo | |
| A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT | NCT04488822 | Tenosynovial Gi... | Pexidartinib | 18 Years - | Daiichi Sankyo | |
| Safety Study of PLX108-01 in Patients With Solid Tumors | NCT01004861 | Solid Tumor | PLX3397 | 18 Years - | Daiichi Sankyo | |
| Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib | NCT04526704 | Tenosynovial Gi... | Pexidartinib | 18 Years - | Daiichi Sankyo | |
| Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer | NCT01596751 | Metastatic Brea... | PLX3397 Eribulin | 18 Years - | University of California, San Francisco | |
| Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC) | NCT01499043 | Prostate Cancer | PLX3397 | 18 Years - | Daiichi Sankyo | |
| PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors | NCT02584647 | Sarcoma Malignant Perip... | PLX3397 Sirolimus | 18 Years - | Columbia University | |
| Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma | NCT01217229 | Hodgkin Lymphom... | PLX3397 | 18 Years - | Daiichi Sankyo | |
| Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib | NCT04526704 | Tenosynovial Gi... | Pexidartinib | 18 Years - | Daiichi Sankyo | |
| A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT | NCT04488822 | Tenosynovial Gi... | Pexidartinib | 18 Years - | Daiichi Sankyo | |
| Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) | NCT01349049 | Acute Myeloid L... | PLX3397 PLX3397 | 18 Years - | Daiichi Sankyo | |
| Safety Study of PLX108-01 in Patients With Solid Tumors | NCT01004861 | Solid Tumor | PLX3397 | 18 Years - | Daiichi Sankyo | |
| A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma | NCT01349036 | Recurrent Gliob... | PLX3397 | 18 Years - | Daiichi Sankyo | |
| Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors | NCT01525602 | Solid Tumors | PLX3397 Paclitaxel | 18 Years - | Daiichi Sankyo | |
| Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) | NCT01349049 | Acute Myeloid L... | PLX3397 PLX3397 | 18 Years - | Daiichi Sankyo | |
| Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer | NCT01596751 | Metastatic Brea... | PLX3397 Eribulin | 18 Years - | University of California, San Francisco | |
| Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS) | NCT02371369 | Pigmented Villo... Giant Cell Tumo... Tenosynovial Gi... | Pexidartinib Placebo | 18 Years - | Daiichi Sankyo | |
| PLX3397 KIT in Acral aNd mucOsal Melanoma | NCT02071940 | Malignant Melan... | PLX3397 | 18 Years - | The Christie NHS Foundation Trust | |
| Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib | NCT04526704 | Tenosynovial Gi... | Pexidartinib | 18 Years - | Daiichi Sankyo | |
| Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib | NCT04526704 | Tenosynovial Gi... | Pexidartinib | 18 Years - | Daiichi Sankyo |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
